GlobeNewswire

Colt Fast-Tracks the Delivery of New Services with Cisco Segment Routing and Ethernet VPN

Dela

LONDON, April 05, 2018 (GLOBE NEWSWIRE) -- Cisco and Colt Technology Services announced today that they have successfully achieved a key milestone in upgrading Colt's pan-European, US and Asian packet network. This lays the foundation for the Colt IQ Network to deliver further differentiated, high-bandwidth connectivity solutions.

Cisco and Colt revealed in December 2016 that they were working on a system-wide, multiple 100Gbps upgrade to Colt's IQ Network.  This will enable it to rapidly deliver high-performance connectivity for cloud-scale, business-critical applications to its enterprise, carrier and web-centric customers. By combining segment routing and Ethernet VPN (EVPN), Colt's IQ Network now benefits from faster convergence time, increased network availability and resiliency for any topology, while enabling the service provider to deliver high-bandwidth solutions much faster.

Colt's next-generation packet network uses end-to-end segment routing technology to simplify and automate network operation and significantly reduce operating costs. With the quality, speed, capacity and flexibility to meet application-specific service quality requirements, Colt's customers will benefit from an infrastructure designed for enabling digital businesses.

"Colt is focused on providing best-in-class, high-bandwidth connectivity solutions to meet our customers' ever-growing business needs," said Peter Coppens, vice president, Product, Colt. "Aligning with these overarching goals, we worked closely with Cisco to design a network architecture that is simple to operate, highly available and capable of delivering innovative network services. This also enables Colt to benefit from faster time-to-market. Segment routing significantly decreased complexity in the IQ Network and helped us start offering differentiated network services such as disjoint path. EVPN further contributed to operational simplification and made the delivery of services much more efficient."

Colt's IQ Network connects more than 800 data centres around the globe, with more than 25,000 on-net buildings, providing high-bandwidth network and voice services for enterprises and wholesale customers in Europe, Asia and North America. EVPN drives the next level of simplicity by offering a unified control plane protocol (Border Gateway Protocol - BGP) for all services types, including both Layer 2 VPN and Layer 3 VPN services. It also provides faster convergence times that significantly enhances the customer experience. Segment routing reduces the network complexity, as it cuts down the number of protocols required. It also:

  • improves network availability with 50ms protection mechanism, covering 100% of the possible network topologies using TI-LFA SR;
  • enables better utilization of the network with simple and scalable MPLS segment routing traffic engineering for the data plane;
  • makes possible the delivery of innovative network services possible, offering on-demand real time delivery capabilities.

The Cisco Network Convergence System (NCS) 5500 series and the Cisco Aggregation Services Router (ASR) 9000 platforms will form the main components of a unified fabric powered by IOS XR and its market-leading software innovations -- segment routing and EVPN.

"We have been working on this initiative with Colt for more than a year, and we are proud to bring additional benefits to its network, as well as lay the groundwork for new opportunities," said Jonathan Davidson, senior vice president and general manager, Service Provider Networking, Cisco. "In selecting Cisco's Cloud Scale Networking technologies such as the Cisco® NCS 5500, segment routing and EVPN, Colt is now in a position to deliver the high bandwidth and customer-oriented experience that defines the network of the future."

Cisco is leading the disruption in the industry with its technology innovations in systems; silicon; software and security; and its unrivalled expertise in mass-scale networking, automation, optical, optics, cable access, video, and mobility. Combining these capabilities with Cisco's portfolio of go-to-market security, collaboration, IoT, and professional services, we enable service providers, media and web companies to reduce cost and complexity, help secure their networks, and grow revenue.

Supporting resources

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. For ongoing news, please go to http://thenetwork.cisco.com.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

About Colt
Colt aims to be the leader in enabling customers' digital transformation through agile and on-demand, high bandwidth solutions. The Colt IQ Network connects over 800 data centres across Europe, Asia and North America's largest business hubs, with over 25,000 on net buildings and growing.

Colt has built its reputation on putting customers first. Customers include data intensive organisations spanning over 200 cities in nearly 30 countries. Colt is a recognised innovator and pioneer in Software Defined Networks (SDN) and Network Function Virtualisation (NFV). Privately owned, Colt is one of the most financially sound companies in its industry and able to provide the best customer experience at a competitive price. For more information, please visit http://www.colt.net.

Press Contacts:

Amy Lucas - Cisco Media  
+44 (0)788 191 8160 amylucas@cisco.com

Nola Pocock - Director - Global Communications, PR & AR
+447917714377 nola.pocock@colt.net




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum